Decisions / 5517
final resolution2022-07-07active

Arzneimittel-Richtlinie/Anlage XII: Abrocitinib (Atopische Dermatitis)

Open official decision page ↗

G-BA source · retrieved 2026-08-05

Structured conclusion

Final result by patient group

1 source-verified result

Patient group

Erwachsene mit mittelschwerer bis schwerer atopischer Dermatitis, die für eine kontinuierliche systemische Therapie in Frage kommen

Hint of considerable added benefit

Comparator
Dupilumab (ggf. in Kombination mit topischen Glukokortikoiden und/oder topischen Calcineurininhibitoren)

Open official result PDF ↗

Decision orientation

What the G-BA did

4 cited claims

Each claim links to the official G-BA page or an exact PDF page range.

Official metadata

Decision date
2022-07-07
Effective
07.07.2022
Action type
final resolution
Committee
Arzneimittel

Case context

Listed normative targets

directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V

A listed target is not treated as a new directive version unless an official version source exists.

Official document package